Johns Hopkins Diabetes Guide
Incretin Mimetics and Amylin Analogues
Incretin Mimetics and Amylin Analogues is a topic covered in the Johns Hopkins Diabetes Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Incretin mimetics also knownn as GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, semaglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
- High-dose liraglutide (Saxenda™) and semaglutide (Wegovy™): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
- Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Incretin mimetics also knownn as GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, semaglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
- High-dose liraglutide (Saxenda™) and semaglutide (Wegovy™): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
- Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 3, 2021
Citation
Patel, Nisha K, et al. "Incretin Mimetics and Amylin Analogues." Johns Hopkins Diabetes Guide, 2021. Johns Hopkins Guide, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/all/Incretin_Mimetics_and_Amylin_Analogues.
Patel NK, Pherson E, Pinto B, Emiliano A. Incretin Mimetics and Amylin Analogues. Johns Hopkins Diabetes Guide. 2021. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/all/Incretin_Mimetics_and_Amylin_Analogues. Accessed October 4, 2022.
Patel, N. K., Pherson, E., Pinto, B., & Emiliano, A. (2021). Incretin Mimetics and Amylin Analogues. In Johns Hopkins Diabetes Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/all/Incretin_Mimetics_and_Amylin_Analogues
Patel NK, Pherson E, Pinto B, Emiliano A. Incretin Mimetics and Amylin Analogues [Internet]. In: Johns Hopkins Diabetes Guide. ; 2021. [cited 2022 October 04]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/all/Incretin_Mimetics_and_Amylin_Analogues.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Incretin Mimetics and Amylin Analogues
ID - 547071
A1 - Patel,Nisha,Pharm.D.
AU - Pherson,Emily,Pharm.D.
AU - Pinto,Brian,Pharm.D.
AU - Emiliano,Ana,M.D.
Y1 - 2021/09/03/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/all/Incretin_Mimetics_and_Amylin_Analogues
DB - Johns Hopkins Guide
DP - Unbound Medicine
ER -
